NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program
January 25 2024 - 8:30AM
NightHawk Biosciences (NYSE American:
NHWK) (“NightHawk” or the “Company”), an integrated
contract development and manufacturing organization (CDMO), today
announced its Scorpius BioManufacturing subsidiary has been awarded
a multimillion-dollar contract to provide process development,
analytical, and cGMP manufacturing services for a publicly traded
biotech company’s Phase 2 clinical program.
Jeff Wolf, CEO of NightHawk Biosciences,
commented, “We are proud to have been selected to help advance this
potentially lifesaving therapy through the clinic. Scorpius has
multiple clients with Orphan Drug Designations from the FDA, and
our San Antonio facility is especially well-suited to advance these
important programs. This new client, needing biologic manufacturing
for a Phase 2 clinical program under cGMP guidelines, will benefit
from Scorpius' comprehensive services in process development,
bioanalysis, and manufacturing. The client, transitioning from a
large CDMO, chose Scorpius to assist in this Phase 2 program based
on our adaptability, dedicated service, and commitment to meeting
project timelines. The scope of work, which includes producing a
monoclonal antibody (mAb) in Scorpius' mammalian facility, is
expected to be completed in 2024. We are extremely pleased with the
success and traction Scorpius gained in 2023, our first full year
in operation, and we are excited to see this momentum continue as
we witness rising demand for our mammalian and microbial
biomanufacturing services.”
NightHawk Biosciences, Inc.
NightHawk Biosciences, through its Scorpius
BioManufacturing subsidiary, is an integrated contract development
and manufacturing organization (CDMO) focused on rapidly advancing
biologic and cell therapy programs to the clinic and beyond.
Scorpius offers a broad array analytical testing, process
development, and manufacturing services to pharmaceutical and
biotech companies at its state-of-the-art facilities in San
Antonio, TX. With an experienced team and new, purpose-built U.S.
facilities, Scorpius is dedicated to transparent collaboration and
flexible, high-quality biologics biomanufacturing. For more
information, please visit: www.nighthawkbio.com or
www.scorpiusbiologics.com, and also follow us on Twitter.
Forward-Looking StatementThis
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions, and include statements such as advancing the
potentially lifesaving therapy through the clinic, the San Antonio
facility being especially well-suited to advance programs with
Orphan Drug Designations from the FDA, the scope of work being
completed in 2024 and seeing the momentum continue as demand rises
for Scorpius’ mammalian and microbial biomanufacturing services.
Important factors that could cause actual results to differ
materially from current expectations include, among others, the
Company’s ability to complete the work as planned, the Company’s
ability to generate future revenue from manufacturing contracts,
the Company’s ability to continue to grow revenue, leverage fixed
costs and achieve long-term profitability,; the Company’s ability
to create substantial shareholder value as a pure-play CDMO in an
underserved marketplace, the Company’s financing needs, its cash
balance being sufficient to sustain operations and its ability to
raise capital when needed, the ability to obtain regulatory
approval or to comply with ongoing regulatory requirements,
regulatory limitations relating to the Company’s ability to
successfully promote its services and compete as a pure- play CDMO,
and other factors described in the Company’s annual report on Form
10-K for the year ended December 31, 2022, subsequent quarterly
reports on Form 10-Qs and any other filings the Company makes with
the SEC. The information in this presentation is provided only as
of the date presented, and the Company undertakes no obligation to
update any forward-looking statements contained in this
presentation on account of new information, future events, or
otherwise, except as required by law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@nighthawkbio.com
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From Apr 2023 to Apr 2024